


# Short-Term Exposure of Cancer Cells to Ultra-High Concentrations of Nitric Oxide (UNO) Activates the mPD-1/mPD-L1 Axis and Immune Response

Yana Epshtein<sup>1</sup>, Matan Goldshtein<sup>1</sup>, Selena Chaisson<sup>1</sup>, Jedidiah M. Monson<sup>1</sup>, Matt Johnson<sup>1</sup>, Gavin Choy<sup>1</sup>, Amir Avniel<sup>2</sup>, Steve Lisi<sup>2</sup>, Hila Confino<sup>1</sup>  
<sup>1</sup>Beyond Cancer, <sup>2</sup>Beyond Air

### Background

We have previously shown that treating mouse colon carcinoma (CT26) tumor-bearing mice with ultra-high concentrations of nitric oxide (UNO) upregulates innate and adaptive immune cells both locally and systemically. Furthermore, we demonstrated that co-treatment of mice with mPD-1 antibody and UNO results in long term tumor regression and survival (Figure 1). In the current study, we assessed mPD-L1 and immune response following short-term exposure to UNO.



### Methods




Figure 2: Schematic representation of *in vitro* and *in vivo* experimental settings. (A) Exposure of CT26 cells to UNO and Flow Cytometry analysis of viability using Annexin-V/PI and PD-L1 expression. (B) Tumor treatment with UNO followed by FACS analysis.

### Results




Figure 3: Cell death mechanism and mPD-L1 expression after exposure to UNO. (A) Apoptotic cell mechanism analysis using Annexin V/PI intracellular staining and (B) mPD-L1 expression on PI-negative cells. Two-way ANOVA, multiple comparison test, \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .




Figure 4: Cell viability and immune profiling of CT26 mice treated with NO 50,000 ppm for 5 minutes. (A) Viability of tumor cells in CT26 tumors treated with 50,000 ppm NO at 1- and 5-days post treatment, (B) Levels of blood M1 macrophages at day 1 after treatment, (C) Tregs in CT26 tumors 1 day after treatment. A,B were analyzed by One-way ANOVA, multiple comparison test, and C was analyzed by Two-way ANOVA \* $P < 0.001$ , \*\* $P < 0.0001$ .

### Conclusions

Short exposure of CT26 cells to UNO results in the upregulation of mPD-L1, suggesting that local treatment with UNO in solid tumors may sensitize “cold” tumor cells within the tumor mass to become responsive to immune checkpoint blockade. In addition, UNO prompts a more favorable local and systemic immune environment that may further enhance anti-tumor response.